Nabiey Romin, Chief Accounting Officer, has demonstrated a consistent pattern of selling activity in shares of GoodRx Holdings, Inc. (GDRX) over the past several years, as reflected in SEC Form 4 filings. Romin has executed 33 trades exclusively involving GDRX, all of which were sales, totaling $167,182.78 in value. Notably, there have been no recorded purchases during this period, indicating a clear selling bias. The transactions span from August 2025 to March 2026, with sales occurring monthly or semi-monthly, often in multiple tranches. For instance, on March 8, 2026, Romin sold shares valued at $2,097.60 and $9,578.28, while earlier sales included $12,724.60 on February 8, 2026, and $14,091.41 on November 8, 2025. These sales were consistently accompanied by transactions coded as "F" (sale), with no corresponding "M" (market) purchases reported. The regularity and volume of these sales suggest a structured approach to divesting shares, possibly tied to prearranged trading plans or stock-based compensation. Romin’s activity is confined to a single company, GDRX, highlighting a focused engagement with this equity holding. The absence of recent buys or sells in the immediate reporting period indicates a pause in trading activity, though the historical trend underscores a sustained disposition of shares over time.
AI-assisted summary